Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 2/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.38 |
| ▸ | WNT3A | P56704 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28285 | 0.84 | ABCG2 (0.44) | KDM4ELMNA | |
| SCHEMBL4552114 | 0.80 | ITGB2 (0.44) | KDM4EITGB2ICAM1ITGALMTNR1A | |
| SCHEMBL7128137 | 0.80 | ITGB2 (0.44) | KDM4EITGB2ICAM1ITGALMTNR1A | |
| SCHEMBL10175066 | 0.76 | CYP3A4 (0.46) | KDM4EITGB2ICAM1ITGALMTNR1A | |
| SCHEMBL31135849 | 0.76 | CYP3A4 (0.46) | KDM4EITGB2ICAM1ITGALMTNR1A | |
| SCHEMBL6210974 | 0.74 | PARP1 (0.51) | — | |
| SCHEMBL17240293 | 0.74 | ITGB2 (0.38) | ITGB2ICAM1ITGALMTNR1ALMNA | |
| SCHEMBL8772483 | 0.73 | KDM4E (0.42) | KDM4EITGB2ICAM1ITGALMTNR1A | |
| SCHEMBL5544393 | 0.72 | ITGB2 (0.50) | KDM4EITGB2ICAM1ITGALMTNR1A | |
| SCHEMBL13062799 | 0.72 | KDM4E (0.45) | KDM4EITGB2ICAM1ITGALMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| CN-1993339-B | Aromatic compound | OTSUKA PHARMA CO LTD | 2013-05-22 | — | — | CN | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| CN-1040436-C | Pharmaceuticals | SMITHKLINE BEECHAM PLC (GB) | 1998-10-28 | — | — | CN | disclosed |
| US-5459142-A | Autoimmune disease, atherosclerosis, antiischemic agents and nephritis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0511879-B1 | Pyrazine derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-03-22 | — | — | EP | disclosed |
| CN-1073173-A | Preparation method as the compound of 5-hydroxytryptamine receptor antagonist | SMITHKLINE BEECHAM PLC (GB) | 1993-06-16 | — | — | CN | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| US-4999378-A | Antilipemic, anticholesterol, antidiabetic, treatment of atherosclerosis and obesity | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-03-12 | — | — | US | disclosed |
| EP-0394440-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | CSF1R, CSF3R, FLT3 | KDM4E 2499/4885ITGB2 1800/4885ICAM1 676/4885 |
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | KDM4E 1219/4885ITGB2 3394/4885ICAM1 2834/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | KDM4E 892/4885ITGB2 2521/4885ICAM1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.